Methylnaltrexone (Relistor): clinical updates from two independent sources
Methylnaltrexone (Relistor) is a peripherally-acting μ-opioid antagonist used for the treatment of opioid induced constipation. Two independent organizations have recently published updated clinical information on this drug: Australian Prescriber. New drugs: Methylnaltrexone Health Canada. Summary Basis of Decision (SBD) RELISTOR The Scottish Medicines Consortium also reviewed Relistor in January 2009.
Methylnaltrexone (Relistor) for opioid induced constipation: SMC review
The Scottish Medicines Consortium issued on 8th December, 2008 an advice on the recently approved opioid antagonist methylnaltrexone ADVICE: following a full submissionMethylnaltrexone (Relistor) is accepted for restricted use within NHS Scotland for treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been […]